Drug Profile
Galicaftor - AbbVie/Galapagos NV
Alternative Names: ABBV 2222; GLPG2222Latest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Developer AbbVie; Galapagos NV
- Class Amides; Antifibrotics; Benzoic acids; Chromans; Cyclopropanes; Dioxolanes; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis
Most Recent Events
- 05 Jul 2023 Abbvie terminates a phase II trial in Cystic fibrosis (Combination therapy, In adults) due to strategic considerations in United Kingdom, Slovakia, Hungary, Germany, Australia, New Zealand, Czech Republic, Netherlands, Belgium and USA (PO) (NCT04853368)
- 21 Dec 2022 AbbVie completes a phase I trial for pharmacokinetics and safety study in healthy subjects in the US (PO) (NCT05538585)
- 29 Nov 2022 AbbVie completes a phase I trial in Healthy volunteers (Combination therapy) in USA (PO) (NCT05530278)